TransCode Therapeutics (RNAZ) News Today $0.32 +0.03 (+11.03%) (As of 01:15 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic CandidateSeptember 17 at 7:00 AM | globenewswire.comTransCode reports progress in metastatic breast cancer treatmentSeptember 13, 2024 | uk.investing.comTransCode Therapeutics (NASDAQ:RNAZ) Earns Buy Rating from HC WainwrightSeptember 9, 2024 | americanbankingnews.comBuy Rating for TransCode Therapeutics Backed by NIH Grant and Promising Treatment EfficacySeptember 5, 2024 | markets.businessinsider.comTransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead CandidateSeptember 5, 2024 | globenewswire.comTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Phase 1 Clinical Trial InitiationAugust 15, 2024 | finanznachrichten.deTransCode Therapeutics Announces Phase 1 Clinical Trial InitiationAugust 15, 2024 | markets.businessinsider.comRNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q2 2024August 15, 2024 | investorplace.comTransCode Therapeutics, Inc. Announces Closing of Public OfferingJuly 24, 2024 | globenewswire.comWhy Transcode Therapeutics (RNAZ) Stock Is Down 60%July 24, 2024 | benzinga.comWhy Is TransCode Therapeutics (RNAZ) Stock Down 62% Today?July 23, 2024 | investorplace.comBiotechnology (Industry) (^YH20610010)July 23, 2024 | finance.yahoo.comTransCode Therapeutics Prices Public Offering Of 10 Mln Shares At $0.30/shrJuly 22, 2024 | markets.businessinsider.comTransCode Therapeutics, Inc. Announces Pricing of Public OfferingJuly 22, 2024 | globenewswire.comTransCode Therapeutics, Inc. Announces Proposed Public Offering of Common StockJuly 22, 2024 | globenewswire.comNasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing RequirementsJune 10, 2024 | globenewswire.comRNAZ Stock Earnings: TransCode Therapeutics Misses EPS for Q1 2024June 3, 2024 | investorplace.comTransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138May 29, 2024 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: TransCode Therapeutics (RNAZ) and Nyxoah (NYXH)May 16, 2024 | markets.businessinsider.comWhy TransCode Therapeutics (RNAZ) Stock Is Getting HammeredMay 13, 2024 | msn.comWhy Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?May 13, 2024 | investorplace.comTransCode Therapeutics Open Letter to ShareholdersMay 13, 2024 | globenewswire.comFDA clears TransCode's drug trial for advanced tumorsApril 17, 2024 | uk.investing.comTransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid TumorsApril 15, 2024 | globenewswire.comPromising Phase 0 Results and Upcoming Trial Boost Confidence in TransCode TherapeuticsApril 4, 2024 | markets.businessinsider.comTransCode Therapeutics Reports 2023 Results; Provides Business UpdateApril 3, 2024 | globenewswire.comTransCode Therapeutics appoints new Chief Medical OfficerMarch 30, 2024 | uk.investing.comTransCode Appoints Daniel Vlock As CMOMarch 29, 2024 | markets.businessinsider.comTransCode Therapeutics, Inc.: TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerMarch 28, 2024 | finanznachrichten.deTransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerMarch 28, 2024 | globenewswire.comTransCode Therapeutics, Inc.: TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentMarch 11, 2024 | finanznachrichten.deTransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentMarch 11, 2024 | globenewswire.comTransCode Therapeutics To Present At 2024 RNA Leaders Europe CongressMarch 6, 2024 | globenewswire.comTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist ImmunotherapeuticFebruary 20, 2024 | finance.yahoo.comTransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist ImmunotherapeuticFebruary 20, 2024 | globenewswire.comTranscode Therapeutics Inc (RNAZ)February 1, 2024 | uk.investing.comNasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock MarketJanuary 31, 2024 | finance.yahoo.comLooking Into TransCode Therapeutics's Recent Short InterestJanuary 30, 2024 | benzinga.comTransCode Collaborates With Debiopharm; Financial Terms Not DisclosedJanuary 29, 2024 | markets.businessinsider.comTransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for CancerJanuary 29, 2024 | finance.yahoo.comTransCode Therapeutics Announces Closing of $7.25 Million Public OfferingJanuary 22, 2024 | finance.yahoo.comWhy TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day SessionJanuary 19, 2024 | msn.comTransCode Therapeutics Shares Slide to 52-Week Low on Planned Public OfferingJanuary 18, 2024 | marketwatch.comTransCode Therapeutics Announces Pricing of $7.25 Million Public OfferingJanuary 18, 2024 | finance.yahoo.comTrading was temporarily halted for "RNAZ" at 01:01 PM with a stated reason of "LULD pause."January 18, 2024 | marketbeat.comTransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-40 Reverse Stock SplitJanuary 15, 2024 | finanznachrichten.deTrading was temporarily halted for "RNAZ" at 07:01 PM with a stated reason of "News pending."January 15, 2024 | marketbeat.comTransCode Therapeutics Stock (NASDAQ:RNAZ) Dividends: History, Yield and DatesJanuary 14, 2024 | benzinga.comStocks to Watch: TransCode Therapeutics, Rackspace Technology, Williams-SonomaJanuary 12, 2024 | marketwatch.comTransCode Therapeutics announces retirement of CEOJanuary 12, 2024 | msn.com Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Is Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! Click here now for the urgent details. RNAZ Media Mentions By Week RNAZ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNAZ News Sentiment▼0.190.68▲Average Medical News Sentiment RNAZ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNAZ Articles This Week▼41▲RNAZ Articles Average Week Get TransCode Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Organovo News Today Cocrystal Pharma News Today ImmunoPrecise Antibodies News Today AIM ImmunoTech News Today Synlogic News Today Iterum Therapeutics News Today Talphera News Today RedHill Biopharma News Today Aptorum Group News Today Cara Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RNAZ) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredJeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredJoin Training: Target 1,000% with One $0.99 election tradeMillionaire Trader Nate Bear is hosting a FREE TRAINING TODAY, where he'll demonstrate how his unique trading ...Monument Traders Alliance | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TransCode Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TransCode Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
